2019 Health & Nutrition finalists
Annaida was founded with a unique mission: to give people the technology to measure what is today inaccessible. Our technology, based on magnetic resonance, can be used to detect and quantify chemical compounds in living microscopic entities, such as human embryos or stem cells, label-free and non-invasively. Annaida is developing a medical device conceived for In Vitro Fertilization and stem-cell organoids, where the need for non-invasive screening and QA methodologies is steadily growing.
Immune rejection remains the most common cause of corneal graft failure. Together with leading ophthalmic specialists, we recently identified ALCAM/CD166 as a promising target for the prevention of corneal graft rejection. We plan to optimize an identified drug candidate and thereafter seek orphan drug designation for assisted progression to phase I clinical trials. Emuna is currently seeking seed financing for EmunaT1 development, validation and patent protection.
The Swiss biotech startup EraCal Therapeutics Ltd. develops a novel anti-obesity drug Era-107 with superior efficacy and safety compared to the standard of care (lorcaserin). An ambitious team with world-class advisors drives the development of Era-107, targeting the first-in-human study in Q4/2021. Our zebrafish-based phenotypic screening platform is applicable to new indications. Now, EraCal, a spin-off of the University of Zurich and Harvard University, is raising funds in seed financing.
Haya Therapeutics SA
HAYA Therapeutics is developing a proprietary anti-fibrotic therapy for myocardial fibrosis and heart failure by targeting a master regulator of fibrosis in the heart, Wisper. Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. HAYA will also implement a target discovery engine to develop a pipeline of lncRNA anti-fibrotic targets in multiple tissues/indications.
Microcaps. Precise microencapsulation at industrial scale. Microcaps offers a novel technology for the production of microparticles and microcapsules used to protect pharmaceutical agents in drugs or fragrances in cosmetic products. With our technology, you can achieve high throughput and precise size control.
Increasing population, life-expectancy and income are major drivers for rising global meat demand. However, the current scale of the meat industry is beyond sustainable. We at Planted have a simple solution to this: we skip the animal and make delicious, healthy and nutritious ‘meat’ directly from plants. Our technology allows us to mimic the fibre lengths of various meat types, to flexibly choose the protein source and to add the juiciness consumers miss with conventional meat analogues.
RetinAI Medical AG
Healthcare is under the pressure of an ever-increasing ageing population, growing faster than the health professionals. This fact increases waiting time in hospitals and, for age-related eye diseases, increases the chance of patients losing eyesight. RetinAI develops tools to make eye hospitals more efficient using AI. We integrate our solution inside clinics' infrastructure & into medical devices, interconnecting the clinical pipeline & reducing the time and cost it takes to evaluate patients.
We aim to develop breakthrough safe and effective therapies for neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of neuronal/glial circuits in the brain. We identified and characterized a new class of small molecules that act as selective endocannabinoid reuptake inhibitors (SERIs). SERIs are protected by 2 patent families that cover a broad chemical space around the scaffold and their medical use.
Sleepiz AG is a Zurich-based startup with the aim to bring revolutionary technology to where it really matters. We develop an end-to-end solution consisting of software and hardware for the medical community. As a medtech-startup, we are backed by clinical experts in Switzerland and centre both, the physician and the patient in our value creation. Our multidimensional sleep monitoring solution measures vital signs in a non-contact and medical grade manner to diagnose sleep disorders at home.
A majority of all cancer therapies fail because of the development of drug resistance. Over time, tumours acquire complex resistance-causing mutations, that make second- and third-line therapies very inefficient. We identified novel mechanisms that predispose cancer cells to the development of drug resistance before it is genetically manifested. Based on this knowledge, we develop add-on therapies that can be combined with cancer drugs at the beginning of therapy to boost its long-term efficacy.